

AT

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/566, A61K 31/00		A1	(11) International Publication Number: WO 98/45708 (43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number:	PCT/US98/06842	(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	7 April 1998 (07.04.98)	(30) Priority Data:	60/043,207 8 April 1997 (08.04.97) US 60/051,715 3 July 1997 (03.07.97) US
(71) Applicant (<i>for all designated States except US</i>):	SUGEN, INC. [US/US]; 515 Galveston Drive, Redwood City, CA 94063 (US).	(72) Inventor; and (75) Inventor/Applicant (<i>for US only</i>):	CLARY, Douglas [US/US]; 164 Midcrest Way, San Francisco, CA 94131 (US).
(74) Agents:	WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		
(54) Title:	STUDY AND TREATMENT OF DISEASES RELATED TO SPECIFIC CELLULAR FUNCTIONS OF RECEPTOR PROTEIN TYROSINE KINASES		
(57) Abstract	<p>The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells by activating the receptor in a ligand independent fashion. In addition, the invention includes methods of identifying compounds that modulate receptor protein tyrosine kinase function. The invention also relates to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neuro-degenerative disorders by administering a compound that modulates the function of the C-RET receptor.</p>		